E. Gabriela Chiorean, MD, FASCO, discusses the FDA approval of encorafenib plus cetuximab and chemotherapy for patients with BRAF V600E–mutated mCRC.
E. Gabriela Chiorean, MD, FASCO
Advertisement
E. Gabriela Chiorean, MD, FASCO, is the clinical director of the GI Medical Oncology Program, professor in the Clinical Research Division, and affiliate investigator in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center. She is also a professor of medicine at the University of Washington and director of the Clinical Research GI Oncology Program at the University of Washington/Fred Hutch.
Articles by E. Gabriela Chiorean, MD, FASCO
E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.
E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses current standard therapeutics for patients with NRG1 fusion–positive pancreatic cancer.
E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer.
E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses prognosis and rarity of patients with NRG1 fusion–positive pancreatic cancer.
E. Gabriela Chiorean, MD, discusses the role of molecular testing in pancreatic cancer.
Advertisement
Latest Updated Articles
Dr. Chiorean on the Role of Molecular Testing in Pancreatic CancerPublished: September 2nd 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5